HIV

Gilead faces revived lawsuit claiming it sidestepped FDA with HIV drug imports
Gilead faces revived lawsuit claiming it sidestepped FDA with HIV drug imports
Fierce Pharma
Gilead Sciences
FDA
HIV
whistleblower lawsuits
Flag link:
Can Merck knock Glaxo off its HIV perch? Maybe so, one analyst says
Can Merck knock Glaxo off its HIV perch? Maybe so, one analyst says
Fierce Pharma
Merck
GSK
HIV
ViiV
EFdA
Flag link:
Janssen gets EU nod for continuous manufacturing
Janssen gets EU nod for continuous manufacturing
BioPharma Dive
Janssen
Europe
drug manufacturing
Prezista
HIV
Flag link:
FDA approves Teva's generic copy of Truvada
FDA approves Teva's generic copy of Truvada
BioPharma Dive
FDA
Teva Pharmaceutical
generics
Truvada
HIV
Gilead Sciences
Flag link:
GSK uses priority voucher to file HIV combo
GSK uses priority voucher to file HIV combo
BioPharma Dive
GSK
priority review
HIV
ViiV
Flag link:
ViiV, GSK gamble a surprise $130M chip in a high-stakes HIV playoff with Gilead
ViiV, GSK gamble a surprise $130M chip in a high-stakes HIV playoff with Gilead
Endpoints
GSK
ViiV
HIV
Flag link:
Gilead racing to FDA with a new HIV cocktail boasting megablockbuster potential
Gilead racing to FDA with a new HIV cocktail boasting megablockbuster potential
Endpoints
Gilead Sciences
FDA
HIV
FTC/TAF
Flag link:
Gilead needs to best Glaxo with bictegravir
Gilead needs to best Glaxo with bictegravir
EP Vantage
Gilead Sciences
GSK
bictegravir
Dolutegravir
HIV
Flag link:
The Worst-Case Scenario for Gilead Sciences, Inc.
The Worst-Case Scenario for Gilead Sciences, Inc.
Motley Fool
Gilead Sciences
M&A
hepatitis C
HIV
Flag link:
Here's Why the Best Is Yet to Come for Gilead Sciences, Inc.
Here's Why the Best Is Yet to Come for Gilead Sciences, Inc.
Motley Fool
Gilead Sciences
HIV
hepatitis C
Flag link:
Napo amps up sales force for AIDS anti-diarrheal
Napo amps up sales force for AIDS anti-diarrheal
BioPharma Dive
Napo
drug reps
AIDS
HIV
Mytesi
Alamo Pharma Services
Flag link:
This Strategy Could Boost GILD’s HIV Franchise Revenue in 2017
This Strategy Could Boost GILD’s HIV Franchise Revenue in 2017
Market Realist
Gilead Sciences
HIV
Flag link:
3 Things Gilead Sciences' CEO Just Said That You'll Want to Know
3 Things Gilead Sciences' CEO Just Said That You'll Want to Know
Motley Fool
Gilead Sciences
Pharma CEOs
John Milligan
hepatitis C
HIV
M&A
Flag link:
Merck’s HIV drug doravirine looks solid — though far less stellar than rivals — in 1st PhIII
Merck’s HIV drug doravirine looks solid — though far less stellar than rivals — in 1st PhIII
Endpoints
Merck
HIV
Doravirine
JNJ
Prezista
Flag link:
Gilead challenges GSK with strong HIV drug data
Gilead challenges GSK with strong HIV drug data
Yahoo/Reuters
Gilead Sciences
GSK
HIV
bictegravir
Dolutegravir
Flag link:
Gilead to use dating sites, Tumblr, and Snapchat in Truvada strategy
Gilead to use dating sites, Tumblr, and Snapchat in Truvada strategy
Medical Marketing and Media
Gilead Sciences
social media
Truvada
HIV
Flag link:
GlaxoSmithKline and Gilead to face off at HIV meeting next week
GlaxoSmithKline and Gilead to face off at HIV meeting next week
Yahoo/Reuters
GSK
Gilead Sciences
HIV
bictegravir
Dolutegravir
Flag link:
Could Gilead Sciences' Game-Changing HIV Pill Solve Its Growth Problem?
Could Gilead Sciences' Game-Changing HIV Pill Solve Its Growth Problem?
Motley Fool
Gilead Sciences
HIV
Truvada
Flag link:
Switching course, Gilead markets HIV drug for prevention
Switching course, Gilead markets HIV drug for prevention
Yahoo/Reuters
Truvada
Gilead Sciences
HIV
Flag link:
Gilead Sciences' HCV Fall Was Partially Offset by HIV Business
Gilead Sciences' HCV Fall Was Partially Offset by HIV Business
Market Realist
Gilead Sciences
hepatitis C
HIV
Flag link: